WEREWOLF THERAPEUTICS, INC. Restructuring Costs
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Restructuring Costs of $1.38 million for the 3-month period ending 2026-06-30, per its S-4 filed 2026-09-22.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. restructuring costs for the quarter ending 2026-06-30 was $1.38M.
- WEREWOLF THERAPEUTICS, INC. restructuring costs for the quarter ending 2026-03-31 was $4.30M.
- WEREWOLF THERAPEUTICS, INC. restructuring costs for the quarter ending 2025-06-30 was $0.00.
- WEREWOLF THERAPEUTICS, INC. restructuring costs for the quarter ending 2025-03-31 was $0.00.
| Period end | Restructuring Costs 3 month | Restructuring Costs 6 month |
|---|---|---|
| 2026-06-30 | $1.38M S-4 · filed 2026-09-22 | $5.68M S-4 · filed 2026-09-22 |
| 2026-03-31 | $4.30M S-4 · filed 2026-09-22 | |
| 2025-06-30 | $0.00 S-4 · filed 2026-09-22 | $0.00 S-4 · filed 2026-09-22 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |